Smart­Dye­Liv­ery devel­ops func­tion­al­ized nanopar­ti­cles in which ther­a­peu­tic com­pounds are enveloped and safely trans­ported to spe­cific organs, which the med­i­cines are tar­get­ing. This patented plat­form deliv­ery tech­nol­ogy can be used for a wide range of ther­a­peu­tic appli­ca­tions and also allows for a unique ther­a­nos­tic use case. Cur­rently the Smart­Dye­Liv­ery team is focus­ing on a ther­apy for sep­sis induced liver fail­ure with the goal of reduc­ing the mor­tal­ity rate of such cases by 90%.

About bm‑t: Erfurt-based, beteili­gungs­man­age­ment Thürin­gen (bm|t) – a sub­sidiary of the Thuringia Devel­op­ment Bank, is the first address for invest­ments in Thuringia, Ger­many. bm‑t cur­rently man­ages eight invest­ment funds with a total vol­ume of 320M EUR. bm‑t invests in inno­v­a­tive com­pa­nies with strong growth poten­tial across all sec­tors and all phases of the cor­po­rate lifecycle.

About Smart­Dye­Liv­ery GmbH: Smart­Dye­Liv­ery GmbH devel­ops nanopar­ti­cle trans­port for ther­a­peu­tic, diag­nos­tic, and ther­a­nos­tic appli­ca­tions. The company´s goal is to save patients´ lives by cre­at­ing new ther­apy options for med­ical con­di­tions that were pre­vi­ously either untreat­able or extremely dif­fi­cult to treat.

You can find more infor­ma­tion about Smart­Dye­Liv­ery at www.smartdyelivery.de